BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

685 related articles for article (PubMed ID: 26920716)

  • 21. Advances in therapies for acute promyelocytic leukemia.
    Kamimura T; Miyamoto T; Harada M; Akashi K
    Cancer Sci; 2011 Nov; 102(11):1929-37. PubMed ID: 21790894
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Alterations of the FLT3 gene in acute promyelocytic leukemia: association with diagnostic characteristics and analysis of clinical outcome in patients treated with the Italian AIDA protocol.
    Noguera NI; Breccia M; Divona M; Diverio D; Costa V; De Santis S; Avvisati G; Pinazzi MB; Petti MC; Mandelli F; Lo Coco F
    Leukemia; 2002 Nov; 16(11):2185-9. PubMed ID: 12399960
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Treatment concepts of acute promyelocytic leukemia.
    Lengfelder E; Saussele S; Weisser A; Büchner T; Hehlmann R
    Crit Rev Oncol Hematol; 2005 Nov; 56(2):261-74. PubMed ID: 16236522
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Role of arsenic trioxide in acute promyelocytic leukemia.
    Iland HJ; Seymour JF
    Curr Treat Options Oncol; 2013 Jun; 14(2):170-84. PubMed ID: 23322117
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Long-term follow-up of treatment outcome and prognosis on 46 children with acute promyelocytic leukemia].
    Xu XJ; Shi SW; Tang YM; Song H; Yang SL; Wei J; Xu WQ; Pan BH; Chen YH; Zhao FY; Shen HQ; Qian BQ; Zhang LY; Ning BT
    Zhongguo Dang Dai Er Ke Za Zhi; 2007 Feb; 9(1):28-33. PubMed ID: 17306073
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Mutations of Epigenetic Modifier Genes as a Poor Prognostic Factor in Acute Promyelocytic Leukemia Under Treatment With All-Trans Retinoic Acid and Arsenic Trioxide.
    Shen Y; Fu YK; Zhu YM; Lou YJ; Gu ZH; Shi JY; Chen B; Chen C; Zhu HH; Hu J; Zhao WL; Mi JQ; Chen L; Zhu HM; Shen ZX; Jin J; Wang ZY; Li JM; Chen Z; Chen SJ
    EBioMedicine; 2015 Jun; 2(6):563-71. PubMed ID: 26285909
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Improved Outcomes With Retinoic Acid and Arsenic Trioxide Compared With Retinoic Acid and Chemotherapy in Non-High-Risk Acute Promyelocytic Leukemia: Final Results of the Randomized Italian-German APL0406 Trial.
    Platzbecker U; Avvisati G; Cicconi L; Thiede C; Paoloni F; Vignetti M; Ferrara F; Divona M; Albano F; Efficace F; Fazi P; Sborgia M; Di Bona E; Breccia M; Borlenghi E; Cairoli R; Rambaldi A; Melillo L; La Nasa G; Fiedler W; Brossart P; Hertenstein B; Salih HR; Wattad M; Lübbert M; Brandts CH; Hänel M; Röllig C; Schmitz N; Link H; Frairia C; Pogliani EM; Fozza C; D'Arco AM; Di Renzo N; Cortelezzi A; Fabbiano F; Döhner K; Ganser A; Döhner H; Amadori S; Mandelli F; Ehninger G; Schlenk RF; Lo-Coco F
    J Clin Oncol; 2017 Feb; 35(6):605-612. PubMed ID: 27400939
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Long term curative effects of sequential therapy with all-trans retinoic acid, arsenious oxide and chemotherapy on patients with acute promyelocytic leukemia.
    Pei R; Cao J; Ma J; Zhang P; Liu X; Du X; Chen D; Sha K; Chen L; Li S; Wu J; Fan Z; Lin L; Ye P; Tang S; Zhang B
    Hematology; 2012 Nov; 17(6):311-6. PubMed ID: 23168069
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Use of all-trans retinoic acid plus arsenic trioxide as an alternative to chemotherapy in untreated acute promyelocytic leukemia.
    Estey E; Garcia-Manero G; Ferrajoli A; Faderl S; Verstovsek S; Jones D; Kantarjian H
    Blood; 2006 May; 107(9):3469-73. PubMed ID: 16373661
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Clinical and laboratory features of patients with CD34(+) acute promyelocytic leukemia].
    Liang JY; Wu DP; Liu YJ; Ma QF; Xue YQ; Zhu MQ; Chen ZX
    Zhonghua Zhong Liu Za Zhi; 2009 Mar; 31(3):196-8. PubMed ID: 19615259
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Can we say farewell to monitoring minimal residual disease in acute promyelocytic leukaemia?
    Grimwade D; Jovanovic JV; Hills RK
    Best Pract Res Clin Haematol; 2014 Mar; 27(1):53-61. PubMed ID: 24907017
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Combination therapy with arsenic trioxide, all-trans retinoic acid, and chemotherapy in acute promyelocytic leukemia patients with various relapse risks.
    Huang H; Qin Y; Xu R; You X; Teng R; Yang L; Xu M; Liu H
    Leuk Res; 2012 Jul; 36(7):841-5. PubMed ID: 22534100
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Arsenic trioxide and all-trans retinoic acid (ATRA) treatment for acute promyelocytic leukemia in all risk groups: study protocol for a randomized controlled trial.
    Zhang X; Zhang H; Chen L; Wang M; Xi J; Liu X; Xie M; Li D; Gulati ES; Gong S; Wang H
    Trials; 2018 Sep; 19(1):476. PubMed ID: 30185214
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Treatment of an acute promyelocytic leukemia relapse using arsenic trioxide and all-trans-retinoic in a 6-year-old child.
    Rock N; Mattiello V; Judas C; Huezo-Diaz P; Bourquin JP; Gumy-Pause F; Ansari M
    Pediatr Hematol Oncol; 2014 Mar; 31(2):143-8. PubMed ID: 24498972
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Long-term survey of outcome in acute promyelocytic leukemia: a single center experience in 340 patients.
    Liu YJ; Wu DP; Liang JY; Qiu HY; Jin ZM; Tang XW; Fu CC; Ma X
    Med Oncol; 2011 Dec; 28 Suppl 1():S513-21. PubMed ID: 21069477
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Treatment for acute promyelocytic leukemia].
    Fujita H
    Rinsho Ketsueki; 2014 Oct; 55(10):1817-26. PubMed ID: 25297745
    [No Abstract]   [Full Text] [Related]  

  • 37. A survival study and prognostic factors analysis on acute promyelocytic leukemia at a single center.
    Xin L; Wan-jun S; Zeng-jun L; Yao-zhong Z; Yun-tao L; Yan L; Chang-chun W; Qiao-chuan L; Ren-chi Y; Ming-zhe H; Jian-xiang W; Lu-gui Q
    Leuk Res; 2007 Jun; 31(6):765-71. PubMed ID: 17007927
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Immunophenotype distinction between acute promyelocytic leukaemia and CD15- CD34- HLA-DR- acute myeloid leukaemia with nucleophosmin mutations.
    Ferrari A; Bussaglia E; Úbeda J; Facchini L; Aventin A; Sierra J; Nomdedéu JF
    Hematol Oncol; 2012 Sep; 30(3):109-14. PubMed ID: 21812014
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Clinical observation of the short-term efficacy of the treatment with combination of all-trans retinoic acid (ATRA) and arsenic trioxide (As2O3) in newly diagnosed acute promyelocytic leukemia (APL)].
    Liu YF; Shen ZX; Chen X; Wang AH; Cao Q; Zhu YM; Chen SJ; Chen Z; Wang ZY
    Zhonghua Xue Ye Xue Za Zhi; 2003 Jan; 24(1):25-7. PubMed ID: 12679006
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Treatment of acute promyelocytic leukemia without cytotoxic chemotherapy.
    Park JH; Tallman MS
    Oncology (Williston Park); 2011 Jul; 25(8):733-41. PubMed ID: 21874835
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 35.